Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Halozyme Therapeutics, Inc.    HALO

Delayed Quote. Delayed  - 07/22 10:00:00 pm
9.24 USD   -1.18%
07/11 HALOZYME THERAP : To Host Second Quarter 2016 Financial Results Conf..
06/08 HALOZYME THERAP : Announces Agreement To Refinance Debt, Increases 2..
06/04 HALOZYME THERAP : Presents Stage One Efficacy And Safety Analysis Of..
News SummaryMost relevantAll newsSector news 

Halozyme Therapeutics, Inc. : Halozyme to Host First Quarter 2012 Financial Results Conference Call

share with twitter share with LinkedIn share with facebook
share via e-mail
04/30/2012 | 10:20pm CEST

SAN DIEGO, April 30, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will webcast its Quarterly Update Conference Call for the first quarter 2012 on Monday, May 7, 2012 at 4:30 p.m. ET/1:30 p.m. PT. Gregory I. Frost, President and Chief Executive Officer, will lead the call. On the same date post-market, Halozyme will release financial results for the first quarter 2012.

(Logo: http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The call will be webcast live through the "Investors" section of Halozyme's corporate website and a recording will be made available following the close of the call. To access the webcast, please log on to www.halozyme.com approximately fifteen minutes prior to the call to register, download, and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (877) 407-8037 (domestic callers) or (201) 689-8037 (international callers). A telephone replay will be available shortly after the call by dialing (877) 660-6853 (domestic callers) or (201) 612-7415 (international callers) using account number 367 and replay ID number 393124.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets HYLENEX® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com.

Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics

SOURCE Halozyme Therapeutics, Inc.

share with twitter share with LinkedIn share with facebook
share via e-mail
07/11 HALOZYME THERAPEUTICS : To Host Second Quarter 2016 Financial Results Conference..
06/08 HALOZYME THERAPEUTICS INC : Entry into a Material Definitive Agreement, Terminat..
06/08 HALOZYME THERAPEUTICS : Announces Agreement To Refinance Debt, Increases 2016 Gu..
06/04 HALOZYME THERAPEUTICS : Presents Stage One Efficacy And Safety Analysis Of Phase..
05/17 HALOZYME THERAPEUTICS : To Present At The UBS 2016 Global Health Care Conference
05/09 HALOZYME THERAPEUTICS INC : Results of Operations and Financial Condition (form ..
05/09 HALOZYME THERAPEUTICS : reports 1Q loss
05/09 HALOZYME THERAPEUTICS : Reports First Quarter 2016 Financial Results
05/06 HALOZYME THERAPEUTICS INC : Material Modification to Rights of Security Holders,..
05/05 HALOZYME THERAPEUTICS : Studies from Halozyme Therapeutics Provide New Data on A..
More news
Sector news : Bio Therapeutic Drugs
07/21DJAmgen and Allergan Study Finds Biosimilar Comparable to Herceptin
07/12DJAmgen Biosimilar Gets Thumbs-Up From FDA Panel
07/12DJJuno to Resume Clinical Trial of Anticancer Treatment
07/09DJCorrections & Amplifications -- WSJ
07/08DJAMGEN : Theranos Dealt Blow as Holmes Is Banned From -2-
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
06/08 Halozyme improves cash position with debt refinance; shares up 2% premarket
06/05 Halozyme's lead product candidate PEGPH20 shows positive results in mid-stage..
05/09 Halozyme Therapeutics' (HALO) CEO Helen Torley on Q1 2016 Results - Earnings ..
05/09 After Hours Gainers / Losers
05/09 Halozyme Therapeutics beats by $0.04, beats on revenue